Krystal Biotech, Inc.
KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treatiā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$197.93
Price-1.02%
-$2.04
1Y
Price
Market Cap
$5.729b
Mid
Price/Earnings 3y Avg5y Avg
29.7x
Premium
Premium
Financials Overview
Key metrics over the past few years+40.9%
EBITDA Margin+39.9%
Net Profit Margin+52.9%
Free Cash Flow MarginRevenue
$359.205m
+23.6%
1y CAGR+165.6%
3y CAGR+124.2%
5y CAGREarnings
$146.725m
+64.6%
1y CAGR+296.0%
3y CAGR+196.7%
5y CAGREPS
$4.92
+64.0%
1y CAGR+280.1%
3y CAGR+191.2%
5y CAGRBook Value
$1.041b
$1.138b
Assets$97.747m
Liabilities$1.617m
DebtDebt to Assets
0.1%
-
Debt to EBITDAFree Cash Flow
$185.443m
+55.6%
1y CAGR+102.9%
3y CAGR+69.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company